What it is
Epithalon (also spelled epitalon) is a short synthetic peptide. It has been studied in cell and animal research for effects on telomerase, an enzyme that maintains telomeres at the ends of chromosomes.
What the research says
- A 2003 study reported that epithalon induced telomerase activity and telomere elongation in human cells in culture [1].
- A 2025 study in human cell lines reported increased telomere length through telomerase upregulation or an alternative lengthening mechanism [2].
- These are laboratory findings. We did not find controlled human trials showing a health outcome.
Regulatory status
Epithalon is research-stage. It is not FDA approved for any use, and compounded versions are not FDA approved. Where prescribed, compounded versions are prepared by state-licensed 503A compounding pharmacies.
Safety and side effects
Telomere biology is complex, and the effect of lengthening telomeres in people is not established. In its July 2026 advisory committee briefing document on epitalon, FDA wrote that "from the mechanistic standpoint, epitalon has the potential to be carcinogenic," because it has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer [3]. A licensed healthcare provider should review your history first, including any personal or family history of cancer.
Is it right for you?
Only a licensed healthcare provider can decide whether any treatment is appropriate for you.
Frequently asked questions
What has epithalon been studied for?
Published research cited here is in human cells in culture and measured telomerase activity and telomere length [1][2]. No health outcome in people has been established.
Is epithalon approved by FDA?
No. Epithalon is not FDA approved and is research-stage. Compounded versions are not FDA approved.
Do I need a prescription for Epithalon?
Yes. Prescription only, requires evaluation by a licensed provider. A provider decides whether it is appropriate for you.
Sources
- Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 2003 (PubMed 12937682). https://pubmed.ncbi.nlm.nih.gov/12937682/
- Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/
- FDA. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: Epitalon-related bulk drug substances. https://www.fda.gov/media/193345/download
Epithalon content on this page is for education. Compounded medications are not FDA approved. Prescription only, requires evaluation by a licensed provider. Educational content only, not medical advice.